Venus Remedies share news, announcements and annual reports
NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap
Venus Remedies Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Dec 2006 on NSE
Last close ₹1,238.60down ₹50.70 (3.93%)BSE ₹1,231.75
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,289.30.
30 Oct: open ₹1,290.00, high ₹1,319.00, low ₹1,225.10
52-week range of traded prices to 30 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,656 Cr1,337th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.35
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.81%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 48,127
Venus Remedies share news and announcements
697 announcements, routine notices left out, newest first. Page 11 of 14.
Aug 2013
5 Aug · Meeting
Register of Members & Share Transfer Books shall remain closed from September 25, 2013 to September 30, 2013 (both days inclusive) for the purpose of Annual General Meeting & determining of entitlement to dividend. Further, the Annual General Meeting of the Company is scheduled to be held on September 30, 2013.
Jul 2013
Jun 2013
19 Jun · Board meeting
Board of Directors of the Company at its meeting held on June 19, 2013, has considered & approved following items :1. Allotment of 9,00,000 equity shares of Rs. 10 each to promoter group company pursuant to conversion of warrants fully convertible into equity shares.2. Re-appointment of Cost Auditor for the FY 2013-14.
May 2013
20 May · Board meeting
Board of Directors of the Company at its meeting held on May 18, 2013 has also approved raising of funds by way of equity/ convertible instruments in the Company/its wholly Owned Subsidiary upto USD 30 million, on a preferential basis, subject to approval of the shareholders, statutory approvals, applicable laws, guidelines and regulations.20 May · Dividend
Board of Directors of the Company at its meeting held on May 18, 2013 have recommended a dividend @ of 30% i.e. Rs. 3/- per share for the financial year ended March 31, 2013 subject to approval of the same by shareholders at the Annual General Meeting.20 May · Results
14 May · Board meeting
Inter alia, to consider and approve :(1) Audited Financial Results for the quarter ended March 31, 2013.(2) Annual Audited Accounts of the Company for the year ended March 31, 2013.(3). Recommendation of dividend for the year 2012-2013.(4) To consider raising of funds by way of equity/convertible instruments etc.
Apr 2013
1 Apr · Board meeting
Board of Directors at its meeting held on March 30, 2013 have approved allotment of 8,00,000 equity shares of Rs. 10 each to promoter group Company pursuant to conversion of warrants fully convertible into equity shares.
Mar 2013
Feb 2013
7 Feb · Management
Board of Directors of Venus Remedies Limited at its meeting held today i.e. February 07, 2013:- Appointed Mr. S. Sengupta as Nominee director of the Company.
Jan 2013
24 Jan · Board meeting
To consider interalia Unaudited Financial Results (Provisional) for the quarter ended December 31, 2012 and to consider any other item with the permission of chair.
Dec 2012
Nov 2012
Oct 2012
23 Oct · Board meeting
To consider interalia Unaudited Financial Results (Provisional) for the quarter ended September 30, 2012 and to consider any other item with the permission of chair.
Sep 2012
Aug 2012
Jul 2012
24 Jul · Board meeting
To consider interalia Unaudited Financial Results (Provisional) for the quarter ended June 30, 2012 and to consider any other item with the permission of chair.
Jun 2012
22 Jun · Meeting
Date of Annual General Meeting is fixed as September 28, 2012. Further the Board also decided that Register of Members and Share Transfer Books shall remain closed from September 24, 2012 to September 28, 2012 (both days inclusive) for the purpose of Annual General Meeting and for the purpose of determining of entitlement to dividend.21 Jun · Dividend
Board of Directors of the Company at its meeting held on June 21, 2012 have recommended a dividend of 30% i.e. Rs. 3/- per share for the financial year ended March 31, 2012 subject to approval of the same by shareholders at the Annual General Meeting.21 Jun · Results
13 Jun · Board meeting
To inter alia consider and approve: (1) Annual Accounts of the Company for the year ended March 31, 2012; (2) Recommendation of dividend for the year 2011-2012; (3) Fix the Date of Annual General Meeting. (4) Any other business with the permission of the Chair.
May 2012
Apr 2012
23 Apr · Board meeting
To consider interalia Unaudited Financial Results (Provisional) for the quarter ended March 31, 2012 and to consider any other item with the permission of Chair.
Mar 2012